Subscribe to RSS
DOI: 10.1055/a-1226-6666
Trastuzumab Biosimilars in the Therapy of Breast Cancer – “Real World” Experiences from four Bavarian University Breast Centres
Article in several languages: English | deutsch
Abstract
Introduction With the introduction of the first trastuzumab biosimilar in the summer of 2018, biosimilar antibodies for breast cancer have found their way into the area of gynaecological oncology. The switch of anti-human epidermal growth factor receptor 2 (HER2) therapy from the reference drug Herceptin® to a biosimilar has presented challenges to the clinics. In addition to structural and organisational measures, training of employees as well as patient briefing and acceptance were major challenges. The study presented here records – within the context of quality assurance – how the switch to a trastuzumab biosimilar was implemented at four Bavarian university clinics in the Purchasing Association of Bavarian University Pharmacies.
Materials/Methods Questionnaires on treatment figures and the switching process were sent to breast centres and pharmacies of four Bavarian university clinics between July and December 2019. The neoadjuvant, adjuvant and metastasised anti-HER2 therapy with trastuzumab with or without pertuzumab was recorded, evaluated and summarised.
Results In the anti-HER2-therapy, trastuzumab was used intravenously (i. v.) and subcutaneously. Between July and December 2018, all four clinics in the Purchasing Association switched the i. v. trastuzumab therapy from the reference drug (Herceptin) to a biosimilar (for 2018: Kanjinti®). Over 200 patients were treated with trastuzumab i. v. in each of the two half-years of 2018 (before and after the switch). The spectrum of side effects and pCR rates under therapy with the biosimilar were comparable to the experiences made with the reference drug. Three out of four clinics provided training to employees and informed patients by means of a defined information leaflet. Patient acceptance was high.
Summary The anti-HER2 therapy could be switched successfully and safely to trastuzumab biosimilars at the Bavarian university hospitals. This may serve as guideline for the further implementation of biosimilars. The structures necessary for this initial switching process have been prepared with trastuzumab as an example.
Supporting Information
- Supporting Information
Questionnaire pharmacies
- Supporting Information
Questionnaire breast centres
Ergänzendes Material
- Supporting Information
Fragebogen Apotheken
- Supporting Information
Fragebogen Brustzentren und onkologische Ambulanzen
Publication History
Received: 29 June 2020
Accepted after revision: 22 July 2020
Article published online:
02 September 2020
© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Stuttgart · New York
-
References/Literatur
- 1 European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products. CHMP/437/04 Rev 1. London, 23 October 2014. Online (last access: 10.08.2019): http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
- 2 Weise M, Bielsky MC, De Smet K. et al. Biosimilars: what clinicians should know. Blood 2012; 120: 5111-5117 doi:10.1182/blood-2012-04-425744
- 3 Kolberg H-C, Colleoni M, Santi P. et al. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Target Oncol 2019; 14: 647-656 doi:10.1007/s11523-019-00675-z
- 4 Markus R, Liu J, Ramchandani M. et al. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community. BioDrugs 2017; 31: 175-187 doi:10.1007/s40259-017-0218-5
- 5 Thill M, Thatcher N, Hanes V. et al. Biosimilars: what the oncologist should know. Future Oncol 2019; 15: 1147-1165 doi:10.2217/fon-2018-0728
- 6 Services USDoHaH. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015. Online (last access: 08.08.2020): http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
- 7 European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. Online (last access: 08.07.2020): https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf
- 8 European Medicines Agency (EMA). Assessment Report: Herzuma®, EMA/44005/2018. Online (last access: 11.08.2020): http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002575/WC500249108.pdf
- 9 von Minckwitz G, Colleoni M, Kolberg HC. et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol 2018; 19: 987-998 doi:10.1016/s1470-2045(18)30241-9
- 10 Pegram MD, Bondarenko I, Zorzetto MMC. et al. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. Br J Cancer 2019; 120: 172-182 doi:10.1038/s41416-018-0340-2
- 11 Stebbing J, Baranau Y, Baryash V. et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol 2017; 18: 917-928 doi:10.1016/s1470-2045(17)30434-5
- 12 Barmer. Barmer Arzneimittelreport 2017. Online (last access: 12.08.2019): https://www.barmer.de/blob/121870/5de7f930ec629f1da7e611d561ccf46a/data/dl-grafik1.jpg
- 13 Barmer. Barmer Arzneimittelreport 2019. Online (last access: 11.08.2020): https://www.barmer.de/blob/195962/b7b2e41d474e012dd5fbfa087f0c0dfb/data/barmer-arzneimittelreport-2019.pdf
- 14 Tabernero J, Vyas M, Giuliani R. et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open 2016; 1: e000142 doi:10.1136/esmoopen-2016-000142
- 15 Aitken M. Delivering on the potential of biosimilar medicines. The role of functioning competitive markets. IMS Institute for Healthcare Informatics; 2016. https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf
- 16 Ludwig WD, Dicheva S. [Biosimilars in oncology: a therapeutic alternative to the reference products?]. Z Gastroenterol 2016; 54: 1223-1229 doi:10.1055/s-0042-117650
- 17 Giuliani R, Tabernero J, Cardoso F. et al. Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. ESMO Open 2019; 4: e000460 doi:10.1136/esmoopen-2018-000460
- 18 Cohen H, Beydoun D, Chien D. et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther 2017; 33: 2160-2172 doi:10.1007/s12325-016-0431-5
- 19 Untch M, Thomssen C, Bauerfeind I. et al. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe Frauenheilkd 2019; 79: 591-604 doi:10.1055/a-0897-6457
- 20 Kolberg H-C, Schneeweiss A, Fehm TN. et al. Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Frauenheilkd 2019; 79: 470-482 doi:10.1055/a-0887-0861
- 21 Janni W, Schneeweiss A, Müller V. et al. Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Frauenheilkd 2019; 79: 268-280 doi:10.1055/a-0842-6661
- 22 AGO Kommission Mamma. Aktuelle Empfehlungen 2020, Version 2020.1D. Online (last access: 11.08.2020): https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma
- 23 Amgen. Fachinformation KANJINTI®. Online (last access: 11.08.2020): https://fachkreise.amgen.de/downloads/f/1/1120/kanjinti-fachinformation.pdf
- 24 European Medicines Agency (EMA). Kanjinti (Trastuzumab). Übersicht über Kanjinti und Begründung für die Zulassung in der EU. EMA/191628/2018. Online (last access: 14.08.2019): https://www.ema.europa.eu/en/documents/overview/kanjinti-epar-medicine-overview_de.pdf
- 25 van Overbeeke E, De Beleyr B, de Hoon J. et al. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists. BioDrugs 2017; 31: 447-459 doi:10.1007/s40259-017-0244-3
- 26 Jacobs I, Singh E, Sewell KL. et al. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence 2016; 10: 937-948 doi:10.2147/ppa.S104891
- 27 Ismailov RM, Khasanova ZD, Gascon P. Knowledge and awareness of biosimilars among oncology patients in Colorado, USA. Future Oncol 2019; DOI: 10.2217/fon-2019-0194.
- 28 Wörmann B, Sinn M. Position of Scientific Oncological Societies Towards Biosimilar Antibodies. Breast Care 2019; 14: 5-8 doi:10.1159/000495145
- 29 Arzneimittelkommission der deutschen Ärzteschaft. Bericht über unerwünschte Arzneimittelwirkungen. Online (last access: 14.08.2019): https://www.dcgma.org/uaw-meldung
- 30 FDA. Biosimilar and Interchangeable Biologics: More Treatment Choices. Online (last access: 11.08.2020): https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices
- 31 European Medicines Agency, European Commission. Biosimilars in the EU. Information guide for healthcare professionals. Online (last access: 11.08.2020): https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf
- 32 Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Leitfaden der Arzneimittelkommission der deutschen Ärzteschaft. Biosimilars. 2017. Online (last access: 11.08.2020): https://www.akdae.de/Arzneimitteltherapie/LF/PDF/Biosimilars.pdf
